Trial Profile

DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary)
Indications Ocular inflammation; Postoperative inflammation
Focus Adverse reactions; Therapeutic Use
Acronyms DEXYCURetro
Sponsors EyePoint Pharmaceuticals

Most Recent Events

16 Nov 2020 Results presented in an EyePoint Pharmaceuticals media release.
16 Nov 2020 According to an EyePoint Pharmaceuticals media release, data from this study were presented at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting.
18 May 2020 According to an EyePoint Pharmaceuticals media release, data from this study were presented in three electronic posters and one oral paper session at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting on May 16-17, 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com